NTRS
35
10
ESS
44
5
HSIC
42
2
PFE
37
4
BLK
46
2
DOW
47
4
VNO
46
6
RCL
74
5
PSX
24
2
MAS
46
3
PSA
43
6
BK
60
2
FCX
44
4
COF
48
3
V
70
14
OKE
61
2
NOV
45
2
DVA
62
5
ILMN
31
4
UNH
42
6
NTRS
35
10
ESS
44
5
HSIC
42
2
PFE
37
4
BLK
46
2
DOW
47
4
VNO
46
6
RCL
74
5
PSX
24
2
MAS
46
3
PSA
43
6
BK
60
2
FCX
44
4
COF
48
3
V
70
14
OKE
61
2
NOV
45
2
DVA
62
5
ILMN
31
4
UNH
42
6
Financhill
Back

Corcept Therapeutics 10K Form

Buy
62

CORT
Corcept Therapeutics

Last Price:
$51.46
Seasonality Move:
11.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-01 10Q CORT/Corcept Therapeutics Quarterly
2023-11-01 10Q CORT/Corcept Therapeutics Quarterly
2023-08-02 10Q CORT/Corcept Therapeutics Quarterly
2023-05-03 10Q CORT/Corcept Therapeutics Quarterly
2022-11-03 10Q CORT/Corcept Therapeutics Quarterly
2022-08-04 10Q CORT/Corcept Therapeutics Quarterly

Receive CORT News And Ratings

See the #1 stock for the next 7 days that we like better than CORT

CORT Financial Statistics

Sales & Book Value

Annual Sales: $482.4M
Cash Flow: $72.2M
Price / Cash Flow: 40.18
Annual Sales: $6.10
Price / Book: 8.44

Profitability

EPS (TTM): 1.26000
Net Income (TTM): $141.8M
Gross Margin: $475.9M
Return on Equity: 25.77%
Return on Assets: 21.04%

Corcept Therapeutics Earnings Forecast

Key Corcept Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 19 years for CORT is 98.66%.
  • The Selling, General & Administrative Expenses for CORT have been equal to 38.20% of Gross Profit Margin.
  • The Research & Development expenses have been 38.22% of Revenue.
  • The Interest Expense is 0.04% of Operating Income.
  • The Net Earning history of CORT is 22.00% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 12 years.

Corcept Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CORT
CUSIP: 218352
Website: corcept.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.7
Quick Ratio: 3.49

Price-to-Earnings

Trailing P/E Ratio: 54.71
Forward P/E Ratio: 30.86

CORT Technical Analysis vs Fundamental Analysis

Buy
62
Corcept Therapeutics (CORT) is a Buy

Is Corcept Therapeutics a Buy or a Sell?